Abstracts tagged "Spondyloarthropathies"

Abstract Number: 0451 • ACR Convergence 2021
Tumor Necrosis Factor Inhibitors Show a Delayed Effect on Radiographic Sacroiliitis Progression in Patients with Early Axial Spondyloarthritis: 10-Year Results from the German Spondyloarthritis Inception Cohort
Murat Torgutalp¹, Valeria Rios Rodriguez¹, Maryna Verba², Mikhail Protopopov¹, Fabian Proft¹, Judith Rademacher¹, Hildrun Haibel³, Martin Rudwaleit⁴, Joachim Sieper³ and Denis Poddubnyy⁵, ¹Charité University Medicine Berlin, Berlin, Germany, ²Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ³Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁵Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Observational cohort studies have shown that there is low, but still detectable progression level in radiographic sacroiliitis, which might also have an impact on…
Abstract Number: 1829 • ACR Convergence 2021
Pharmacological Treatment of Enthesitis – A Systematic Review on the Efficacy of the Available Options
Rita Torres¹, Santiago Manica² and Fernando Santos², ¹Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, ²Hospital Egas Moniz, Lisboa, Portugal
Background/Purpose: Enthesitis is a recognized as a hallmark of spondyloarthrtis (SpA), including psoriatic arthritis (PsA). However, it is an underestimated disease domain in both in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].